logo
Radical New Theory Rewrites the Story of the Earliest Universe

Radical New Theory Rewrites the Story of the Earliest Universe

Gizmodo7 days ago
Following the Big Bang, our universe expanded at an exponential rate. According to this theory, known as cosmic inflation, the explosive growth produced tiny quantum fluctuations that later evolved into galaxies. Cosmic inflation neatly explains how our universe got so large and mostly homogenous, and that's why it's remained a strong theory in cosmology for decades.
But it's far from perfect. Cosmic inflation depends on certain theoretical assumptions that can get rather arbitrary—not ideal for a theory that's supposed to explain why our universe appears the way it does. It's this shortcoming that motivated theoretical physicist Raúl Jiménez from the University of Barcelona in Spain to devise an alternative approach to decoding the dynamics of the very early universe. The resulting proposal, published earlier this month in Physical Review Research, seeks to eliminate the excessive, circumstantial parameters in traditional models that have made it difficult for physicists to agree on a single theory.
The proposal, developed by Jiménez and colleagues, is a relatively simple paradigm founded mostly on well-understood principles of quantum mechanics and general relativity. It starts with the assumption that the very early universe existed in what's called a De Sitter space, which sees the universe as a flat-shaped vacuum governed by general relativity. According to quantum mechanics, applying some energy to this—namely the Big Bang—generates quantum fluctuations that give rise to tensor modes, or gravitational waves. These waves organically seeded small bits of density throughout the universe, and those little bits eventually evolved into galaxies, stars, and planets, according to the theory.
Critics of traditional inflationary theory argue that it has too many adjustable parameters. One such parameter is the inflaton—hypothetical scalar fields that physicists believe drove rapid expansion in the early universe. But the new theory removes the inflaton from the picture, substituting it with a de Sitter space rocked by gravitational waves.
That the new theory removes many adjustable parameters is a big bonus. 'There is no general principle that determines these things, so basically you need to put them in by hand,' explained Arthur Kosowsky, a cosmologist at the University of Pittsburgh not involved in the new work, in an email to Gizmodo. 'Physicists always strive to make models and theories which are in some sense as simple as possible, meaning that the number of arbitrary things you need to put in by hand is as small as possible.'
In an ideal world, a solid theory or model shouldn't require so many adjustable variables. A similar problem exists with the all-encompassing Standard Model, which features a whopping 18 free parameters that need to be sorted out every single time. Physicists 'expend lots of blood, sweat, and tears (and money) because most people are convinced that there must be a better, more powerful model which has two or three parameters instead of 18,' Kosowsky said.
And indeed, finding a simple, compelling explanation for early cosmic inflation is what motivated the new work, Jiménez told Gizmodo during a video call. The strength of this theory is that it is 'fully falsifiable' in the sense that it either can or cannot explain observational data, he said. However, this is also the theory's weakness, which Jiménez acknowledged: 'Maybe nature didn't choose this theory as the way things work.'
Of course, the most valuable thing about falsifiable theories is that they tell us what doesn't work, he added. (While this might seem sketchy, physicists often employ something akin to a process of elimination for unknown phenomena, such as dark matter.) As for Jiménez's newly proposed theory, it's fair to ask whether it will hold up to observational data and survive further mathematical scrutiny.
What Is Dark Matter and Why Hasn't Anyone Found It Yet?
'I like the overall philosophy driving this paper, [which is] 'let's see if we can come up with a situation where inflation arises naturally out of some basic physics,'' Kosowsky said. 'If we can, this is both more elegant than adding some speculative and, in some sense, arbitrary physical elements and also is likely to make more specific predictions, which can then hopefully be compared with observations.'
'I believe it's an interesting and novel proposal—it's something that's well worth a closer look,' commented Andrew Liddle, a theoretical cosmologist at the Institute of Astrophysics and Space Sciences (IA) at the University of Lisbon in Portugal, during a video call with Gizmodo. At the same time, its simplicity could also be its biggest flaw, but only time will tell if more mathematically minded cosmologists take a liking to it, he said.
'There have always been cosmologists who are uncomfortable with inflation [theory]. I'm one of them—and I work on it,' said Marina Cortês, also with the IA, in the same call. 'One of the most uncomfortable things about inflation is that physicists understand everything from the Big Bang onwards, but not the Big Bang and the earliest stages.'
Liddle and Cortês, both uninvolved in the new work, said that while cosmologists (including themselves) often disagree on how to best interpret cosmic inflation, the evidence seems to support the notion that inflation did in fact take place. Many physicists have devised alternative explanations, but practically everything has ended up in a 'dustbin' of discarded ideas, Liddle explained.
'But there's no limit to people's imagination,' Liddle said. And the next few decades should see no shortage of new ideas and models—just like this one, according to the two cosmologists.
'Cosmology right now is mostly about these things called tensions, or hints that things are not quite well aligned with the standard cosmological model,' Liddle said. Several questions threatening to usurp what we know about the physical universe—dark energy, the Hubble tension—appear to be coming together in one paradoxical package for scientists, and inflation could be a part of that, Cortês added.
No matter what happens, it goes without saying that we're witnessing a time of excitement, chaos, and discovery for cosmology—a sentiment that all the scientists agreed on.
'Not only is the data growing at exponential amounts, but the quality of the analysis is also growing at an exponential quality,' Jiménez said. 'I think that we are living a golden age of cosmology.'
'When we are thinking about inflation, we are trying to take the next step and answer the question of why the universe looks the way it does, and not just describe how it looks,' Kosowsky said. 'Is this due to some deep physics principle yet undiscovered? It could be, and this is what keeps us working hard to push back the boundaries of our understanding.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Clinical Evaluation of Medical Devices: The Clinical Evaluation Report (2-Day Online Training Course with 12 CPD Hours: November 25-26, 2025)
Clinical Evaluation of Medical Devices: The Clinical Evaluation Report (2-Day Online Training Course with 12 CPD Hours: November 25-26, 2025)

Yahoo

time34 minutes ago

  • Yahoo

Clinical Evaluation of Medical Devices: The Clinical Evaluation Report (2-Day Online Training Course with 12 CPD Hours: November 25-26, 2025)

Join this comprehensive course on clinical evaluation aligned with European MDR, offering tools to craft high-quality Clinical Evaluation Reports (CER) for medical devices. Gain expertise in data collection, analysis, and regulatory compliance. Includes case studies and templates. Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Clinical Evaluation of Medical Devices: The Clinical Evaluation Report Training Course" has been added to offering. This introductory course will cover all aspects of clinical evaluation in line with the European Medical Device Regulation (MDR) and applicable guidance documents. The programme will provide you with the tools and skills you will need to produce a high-quality clinical evaluation report (CER) for all your medical devices. You will understand the detail of what clinical data is needed, how to collect it, analyse it and receive direction on producing a CER that is acceptable to the regulatory authorities and Notified Bodies. You will learn how the process fits into the development of a medical device and also the post-market aspects of clinical evidence. The programme includes case studies and template documents which you will be able to utilise to produce your own clinical data evidence documentation. Benefits of attending: Gain a detailed overview of the clinical evaluation process Understand the concepts involved in conducting a clinical evaluation Learn how to utilise information gathered during a clinical evaluation Take away skills in conducting systematic literature searches Understand where clinical evaluation fits into the development and marketing of medical devices Explore how to appraise data Know how to assemble clinical evidence acceptable for review by regulatory authorities or Notified Bodies Certifications: CPD: 12 hours for your records Certificate of completion Who Should Attend: CROs Medical writers Clinical staff Those who conduct clinical evaluations/investigations/post-market follow-up studies Those moving from pharmaceuticals to medical devices And personnel involved in: Gathering clinical evidence and conducting clinical evaluations R&D Regulatory affairs Key Topics Covered What is a clinical evaluation? Explanation of the terminology used in clinical evaluations Overview of a clinical evaluation The importance of clinical evidence in medical device development Why and when is it necessary to conduct a clinical evaluation? Where does clinical evaluation sit within the medical device process? Why is clinical evidence important? Who are the stakeholders in the process? Who and what is involved in the clinical evaluation process? Overview of each step Use of equivalent products Workshop: bringing it together An interactive exercise on what has been learnt so far What regulations govern clinical evaluations and what guidance documents should clinical evaluations be conducted to? An in-depth review of the available regulatory and guidance documents which can be utilised during the process and how to interpret these Documentation necessary for conducting a clinical evaluation The clinical evaluation plan The literature review process Selecting databases and conducting searches How to source data and review it How to clarify the question on which you need to find literature, including devising the most comprehensive literature search strategy and selecting keywords The Clinical Evaluation Report (CER) What is it and what is included? Who should write it? How to write it What is state of the art and how to conduct a risk benefit assessment of the data? Performance and safety analysis State-of-the-art analysis Risk-benefit analysis Impact of the Medical Device Regulations (MDR) For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure
EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure

Yahoo

time4 hours ago

  • Yahoo

EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure

FOR IMMEDIATE RELEASE EnduroSat and Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure Sofia, Bulgaria & Geneva, Switzerland – July 28, 2025 – WISeKey International Holding AG (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, via its subsidiary AG, a company that focuses on space technology for secure satellite communication, specifically for IoT applications, and EnduroSat, a leading provider of software-flexible satellites, as part of their strategy to diversify partners in the industry, are pleased to announce the signing of a Memorandum of Understanding (MoU) to establish a framework aimed at achieving a strategic partnership to extend the development and deployment of ultra-secure, quantum-resilient nanosatellite systems for Internet of Things (IoT) applications. The cooperation targets the integration of SEALSQ secure elements, such as the VaultIC292, VaultIC408, and QS7001, into satellite payloads and ground-level endpoints. These components enable strong hardware-based security and digital identity protection, ensuring encrypted communications and trusted authentication across the IoT satellite network. The project aims to implement post-quantum cryptographic (PQC) algorithms, aligned with NIST recommendations such as CRYSTALS-Kyber and CRYSTALS-Dilithium, to safeguard against future quantum computing threats. WISeSat will provide the PQC algorithmic stack and support, while EnduroSat will incorporate these into its satellite and communication platform. EnduroSat brings its expertise in modular satellite design, in-orbit validation, and scalable deployment systems. It will lead the physical integration of SEALSQ secure components into next-generation satellite buses and contribute to the overall mission architecture. WISeSat will support cryptographic integration and field engineering resources, ensuring that each system meets high-security and resilience benchmarks. The partnership further outlines the future integration of post-quantum cryptographic solutions and secure elements into both EnduroSat and WISeSat satellite infrastructures. EnduroSat will also support the design and deployment of WISeSat's future missions, ensuring compliance with defined security and performance requirements. This collaboration builds on WISeSat's successful deployment of its new-generation PQC-ready nanosatellite in December 2025 and EnduroSat's proven record of delivering more than 60+ satellites to orbit for institutional, scientific, and commercial customers. The resulting architecture will offer scalable, tamper-proof IoT connectivity services from Low Earth Orbit (LEO), critical for use-cases in logistics, critical infrastructure, defense, and environmental monitoring. 'This partnership with EnduroSat marks a significant step forward in our mission to deliver quantum-resilient, end-to-end secure satellite infrastructure,' said Carlos Moreira, Founder and CEO of WISeKey. 'By integrating SEALSQ's advanced secure elements into the expanding WISeSat constellation, we are building a tamper-proof communications backbone in space. Together with EnduroSat's modular satellite technology, we are enabling scalable and ultra-secure IoT connectivity services from Low Earth Orbit—critical for securing data and infrastructure in the quantum era.' 'We are excited to initiate this partnership,' said Raycho Raychev, founder & CEO of EnduroSat. 'We hope to accelerate the introduction and establishment of much stronger encryption capabilities into the satellite industry.' About AG is pioneering a transformative approach to IoT connectivity and climate change monitoring through its innovative satellite constellation. By providing cost-effective, secure, and global IoT connectivity, WISeSat is enabling a wide range of applications that support environmental monitoring, disaster management, and sustainable practices. The integration of satellite data with advanced climate models holds great promise for enhancing our understanding of climate change and developing effective strategies to combat its impacts. As the world continues to grapple with the challenges of climate change, initiatives like WISeSat's IoT satellite constellation are essential for creating a more resilient and sustainable future. About WISeKeyWISeKey International Holding Ltd ('WISeKey', SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) Corp which focuses on trusted blockchain NFTs and operates the marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform. Each subsidiary contributes to WISeKey's mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company's semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey's strategic direction and its subsidiary companies, please visit About EnduroSatEnduroSat is a space infrastructure builder that engineers, builds, and operates exceptional satellites. The company streamlines space missions in LEO and beyond, handling every step from mission design to launch and operations. EnduroSat serves more than 360 customers globally and employs more than 230 space professionals across 6 locations worldwide. For more information, visit DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ('FinSA'), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Press and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@ WISeKey Investor Relations (US) The Equity Group CatiTel: +1 212 836-9611 lcati@ ENDUROSAT EADCompany Contact: Raycho RaychevFounder & CEOinfo@

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

Yahoo

time4 hours ago

  • Yahoo

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Both studies are part of Azafaros' mission to develop treatments for the unmet need of patients with rare lysosomal storage disorders The news follows the company's recent successful €132M Series B financing, aimed at supporting the rapid development of nizubaglustat and the expansion of Azafaros' pipeline to other indications LEIDEN, Netherlands, July 28, 2025--(BUSINESS WIRE)--Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. "The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy." About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. View source version on Contacts For further information: Azafaros info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store